Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:KURA NASDAQ:KYTX NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$11.94+0.3%$10.64$7.80▼$28.09$651.48MN/A304,823 shs189,264 shsKURAKura Oncology$7.90-2.1%$6.43$5.41▼$21.57$685.70M0.411.94 million shs1.68 million shsKYTXKyverna Therapeutics$3.71+0.3%$3.53$1.78▼$8.28$160.44M3.05277,974 shs322,823 shsSIGASiga Technologies$8.39+2.2%$7.42$4.95▼$9.62$600.77M0.94670,746 shs354,801 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics0.00%+0.84%+7.47%+28.66%+1,193,999,900.00%KURAKura Oncology0.00%+3.27%+30.58%+39.08%-60.77%KYTXKyverna Therapeutics0.00%-3.64%+3.92%+47.22%-52.25%SIGASiga Technologies0.00%-8.11%+26.93%+39.60%-8.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara Therapeutics1.702 of 5 stars3.50.00.00.01.50.80.6KURAKura Oncology3.9349 of 5 stars3.43.00.04.72.50.00.6KYTXKyverna Therapeutics2.3467 of 5 stars3.62.00.00.02.11.70.6SIGASiga Technologies2.413 of 5 stars0.02.00.00.03.50.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$32.25170.11% UpsideKURAKura Oncology 2.86Moderate Buy$24.10205.06% UpsideKYTXKyverna Therapeutics 3.14Buy$16.60347.44% UpsideSIGASiga Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KYTX, KURA, SIGA, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $10.008/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.008/20/2025KYTXKyverna TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform8/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/12/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.008/11/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$28.00 ➝ $24.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.98 per shareN/AKURAKura Oncology$83.28M8.23N/AN/A$3.52 per share2.24KYTXKyverna Therapeutics$7.03M22.82N/AN/A$4.26 per share0.87SIGASiga Technologies$138.72M4.33$0.84 per share10.03$2.92 per share2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)KURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.426.71N/A45.73%40.52%35.62%11/6/2025 (Estimated)Latest KYTX, KURA, SIGA, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/12/2025Q2 2025KYTXKyverna Therapeutics-$1.00-$0.97+$0.03-$0.97N/AN/A8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A25.8025.80KURAKura Oncology0.026.166.16KYTXKyverna TherapeuticsN/A5.395.39SIGASiga TechnologiesN/A10.098.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/AKURAKura OncologyN/AKYTXKyverna Therapeutics18.08%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%KURAKura Oncology6.40%KYTXKyverna Therapeutics22.00%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.56 million46.11 millionN/AKURAKura Oncology13086.80 million81.24 millionOptionableKYTXKyverna Therapeutics9643.25 million33.73 millionOptionableSIGASiga Technologies4071.61 million70.21 millionOptionableKYTX, KURA, SIGA, and BCAX HeadlinesRecent News About These CompaniesHealthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse...August 30 at 10:04 PM | marketbeat.comSiga Technologies Inc. $SIGA Shares Acquired by American Century Companies Inc.August 30 at 3:42 AM | marketbeat.comHotchkis & Wiley Capital Management LLC Increases Stock Position in Siga Technologies Inc. $SIGAAugust 26, 2025 | marketbeat.comSiga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)August 23, 2025 | marketbeat.comFirst Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGAAugust 21, 2025 | marketbeat.comSIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA NewsAugust 20, 2025 | seekingalpha.comSiga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?August 15, 2025 | marketbeat.comWall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-BuyAugust 10, 2025 | marketbeat.comSIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)August 8, 2025 | finance.yahoo.comSiga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's WhyAugust 7, 2025 | marketbeat.comSIGA (SIGA) Q2 Revenue Soars 272%August 7, 2025 | theglobeandmail.comSiga Technologies (NASDAQ:SIGA) Issues Earnings ResultsAugust 6, 2025 | marketbeat.comSIGA Technologies (SIGA) Reports Significant Earnings DeclineAugust 6, 2025 | finance.yahoo.comSIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA fundingAugust 6, 2025 | msn.comSIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Six Months Ended June 30, 2025August 5, 2025 | globenewswire.comSIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 ResultsJuly 29, 2025 | globenewswire.comSiga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to KnowJuly 24, 2025 | zacks.comSiga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should KnowJuly 15, 2025 | msn.comUS Market's Undiscovered Gems Featuring Three Promising Small CapsJuly 15, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Laps the Stock Market: Here's WhyJuly 9, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, KURA, SIGA, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$11.94 +0.03 (+0.25%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$11.93 -0.01 (-0.08%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Kura Oncology NASDAQ:KURA$7.90 -0.17 (-2.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.03 +0.13 (+1.59%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Kyverna Therapeutics NASDAQ:KYTX$3.71 +0.01 (+0.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.72 +0.00 (+0.13%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Siga Technologies NASDAQ:SIGA$8.39 +0.18 (+2.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.38 -0.02 (-0.18%) As of 08/29/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
